29/06 | US Futures Marginally Higher Ahead of Final Q1 GDP Reading |  |
27/06 | ARGENX : Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patien.. |  |
27/06 | Argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie.. |  |
24/06 | Argenx Gets Positive CHMP Opinion for Generalized Myasthenia Gravis Drug |  |
24/06 | Argenx Gets EU Committee's Positive Opinion For Generalized Myasthenia Gravis Treatment |  |
24/06 | argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie.. |  |
24/06 | Argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie.. |  |
17/06 | European ADRs Move Lower in Friday Trading |  |
16/06 | TRANSCRIPT : Argenx SE Presents at Goldman Sachs 43rd Annual Global Healthcare Conference,.. |  |
07/06 | European ADRs Move Higher in Tuesday Trading |  |
03/06 | European ADRs Move Lower in Friday Trading |  |
01/06 | argenx to Present at Upcoming Investor Conferences |  |
01/06 | Argenx to Present at Upcoming Investor Conferences |  |
31/05 | Argenx's Generalized Myasthenia Gravis Therapy Gets Positive Scientific Opinion By UK W.. |  |
31/05 | argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized M.. |  |
31/05 | Argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized M.. |  |
19/05 | argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin B.. |  |
19/05 | argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin B.. |  |
19/05 | Argenx SE Announces Publication of Translational Data of Efgartigimod in Autoimmune Ski.. |  |
13/05 | ACTUALIZACIÓN DE LAS GRANDES EVOLUCI : final de la semana en verde |  |
13/05 | European ADRs Move Higher in Friday Trading |  |
13/05 | POINT SUR LES FORTES VARIATIONS DU J : fin de semaine dans le vert |  |
13/05 | POINT SUR LES FORTES VARIATIONS DU J : Somfy remercie MSCI, UCB maudit la FDA |  |
13/05 | Ça va piquer, mais on n'a pas le choix |  |
13/05 | AVIS D'ANALYSTES DU JOUR : TotalEnergies, Roche, Ubisoft, ArgenX, SMA Solar, SoftwareOne, .. |  |
11/05 | TRANSCRIPT : Argenx SE Presents at Bank of America 2022 Healthcare Conference, May-11-2022.. |  |
11/05 | Investitionen verhageln Evotec das Ergebnis - Aktie im Sinkflug |  |
10/05 | argenx announces results of Annual General Meeting of Shareholders |  |
10/05 | Argenx announces results of Annual General Meeting of Shareholders |  |
10/05 | European ADRs Move Higher in Tuesday Trading |  |
05/05 | SECTOR UPDATE : Health Care Stocks Tumbling in Late Trade |  |
05/05 | SECTOR UPDATE : Health Care Stocks Dropping in Afternoon Trade |  |
05/05 | Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART(R).. |  |
05/05 | European ADRs Decline in Thursday Trading |  |
05/05 | SECTOR UPDATE : Health Care Stocks Decline Premarket Thursday |  |
05/05 | TRANSCRIPT : Argenx SE, Q1 2022 Earnings Call, May 05, 2022 |  |
05/05 | POINT SUR LES FORTES VARIATIONS DU J : mini-séisme pour CGG, Airbus à haute altitude |  |
05/05 | Argenx Says Vyvgart Drug Improved Platelet Count in Patients With Bleeding Disorder |  |
05/05 | Argenx Q1 Loss Widens |  |
05/05 | Argenx's Bleeding Disorder Drug Improves Platelet Count in Late-Stage Study |  |
05/05 | Argenx Forecasts $1 Billion Cash Utilization in FY22 |  |
05/05 | argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alf.. |  |
05/05 | argenx Reports First Quarter 2022 Financial Results and Provides Business Update |  |
05/05 | Argenx Reports First Quarter 2022 Financial Results and Provides Business Update |  |
05/05 | Argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alf.. |  |
05/05 | Argenx SE Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod .. |  |
05/05 | Argenx SE Reports Earnings Results for the First Quarter Ended March 31, 2022 |  |
04/05 | argenx to Present at BofA Securities 2022 Healthcare Conference |  |
04/05 | Argenx to Present at BofA Securities 2022 Healthcare Conference |  |
28/04 | ARGENX : argenx to Report First Quarter 2022 Financial Results and Business Update on May .. |  |
28/04 | Argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 20.. |  |
22/04 | BB Biotech plombé au 1er trimestre par des marchés capricieux |  |
05/04 | Argenx SE Says Long-Term Vyvgart Treatment Reduces Generalized Myasthenia Gravis Sympto.. |  |
05/04 | Argenx's Myasthenia Gravis Drug Shows Improved Disease Scores In Late-stage Extension T.. |  |
05/04 | Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGA.. |  |
05/04 | Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGA.. |  |
01/04 | argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American .. |  |
01/04 | Argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American .. |  |
30/03 | Argenx's Capital Raise Grows To $805 Million After Underwriters Exercise Option |  |
29/03 | Argenx announces full exercise of underwriters' option to purchase additional ADSs |  |
29/03 | Argenx announces Annual General Meeting of Shareholders on May 10, 2022 |  |
29/03 | Argenx Raises $700 Million Via Share Issue |  |
28/03 | argenx announces closing of global offering |  |
25/03 | ARGENX : announces launch of proposed global offering - Form 6-K |  |
24/03 | Argenx Prices $700 Million Global Offering |  |
24/03 | Argenx Prices $700 Million Global Offering |  |
24/03 | Argenx raises $700 million in gross proceeds in a global offering |  |
23/03 | Argenx Initiates $500 Million Global Share Offering |  |
22/03 | Argenx Launches $500 Million Stock Offering; Shares Down 4% After Hours |  |
22/03 | argenx announces launch of proposed global offering |  |
22/03 | SECTOR UPDATE : Health Care Stocks Mixed on Tuesday |  |
22/03 | Halozyme Therapeutics Says Argenx's Phase 3 Trial in Generalized Myasthenia Gravis Meet.. |  |
22/03 | ARGENX : Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneo.. |  |
22/03 | Argenx SE Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcut.. |  |
22/03 | TRANSCRIPT : Argenx SE - Special Call |  |